Substance / Medication

Vorasidenib

Overview

Active Ingredient
vorasidenib
RxNorm CUI
2690647

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
4
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.
Himstead Alexander S, Chen Jefferson W, Chu Eleanor et al. · Biomedicines · 2025
PMID: 39857783Case ReportFull text (PMC)
Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions.
Pan Zhenjiang, Bao Jing, Wei Shepeng · Front Oncol · 2025
PMID: 40657255ReviewFull text (PMC)
Who will benefit from vorasidenib? Review of data from the literature and open questions.
Darlix Amélie, Preusser Matthias, Hervey-Jumper Shawn L et al. · Neurooncol Pract · 2025
PMID: 39776530ReviewFull text (PMC)
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.
de la Fuente Macarena I, Touat Mehdi, van den Bent Martin J et al. · Neuro Oncol · 2025
PMID: 39723472ReviewFull text (PMC)
Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
Dipasquale Angelo, Giordano Pasqualina, Bosio Alberto et al. · J Neurooncol · 2026
PMID: 41604034Other
Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.
Silva Gabriel Vinícius Rolim, Aktaruzzaman M, Fulco Umberto Laino et al. · Int J Surg · 2025
PMID: 40171567OtherFull text (PMC)
INDIGO and Beyond: Approaching Vorasidenib With Cautious Optimism.
Touat Mehdi · Int J Radiat Oncol Biol Phys · 2025
PMID: 40382162Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Vorasidenib (substance)
SNOMED CT
933316181000036101
UMLS CUI
C4726974
RxNorm CUI
2690647

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.